TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ≥ 18 years of old.~2. Clinical diagnosis of type 1 diabetes for at least one year.~3. The subject will have been on insulin pump therapy for at least 3 months.~4. HbA1c ≤ 12%.~Exclusion Criteria:~1. Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator~2. Recent (\< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery~3. Warfarin chronic treatment if INR monitoring cannot be evaluated (can increase the risk of bleeding)~4. Chronic use of acetaminophen. Acetaminophen may interfere with glucose sensor readings~5. Pregnancy (ongoing or current attempt to become pregnant)~6. Breastfeeding~7. No nearby party for assistance if needed~8. Plans to go abroad or travel at more than 2 hours distance from Montreal during the trial period~9. Severe hypoglycemic episode within two weeks of screening or during the run-in period~10. Severe hyperglycemic episode requiring hospitalization in the last 3 months~11. Current use of glucocorticoid medication (except low stable dose and inhaled steroids)~12. Known or suspected allergy to the trial products~13. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator~14. Anticipation of a significant change in exercise regimen between admission and end of the trial (i.e. starting or stopping an organized sport)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sensor-augmented pump therapy (Type: ACTIVE_COMPARATOR): Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
- Single-hormone closed-loop strategy (Type: ACTIVE_COMPARATOR): Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MEDTRUM A7+ TouchCare Insulin Patch Pump (MedInPS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with type 1 or 2 diabetes, 18 years of age and over~* Patients already equipped with Omnipod® ® (INSULET) insulin patch pump and Abbott FreeStyleLibre sensor®.~* A1C ranking from : \>= 6,5% to \<= 9.5%~* Any type of rapid insulin except FIASP (which can be substituted if necessary) with 60 IU max per day (unauthorized use of insulin supplements by pen injector)~* Patient able to receive and understand study information, give written informed consent, and easily participate to the trial~* Patient affiliated to the French social security system~Exclusion Criteria:~* - Patient already participating in another study~* Patient under the protection of justice or under guardianship or curatorship~* Type 2 diabetic patient requiring a daily insulin dose \> 60 IU~* Patients not suitable for suing insulin pump such as: severe psychiatric disorders, rapidly progressing ischemic or proliferative retinopathy before laser treatment, and exposure to high magnetic ﬁelds~* Patients allergic to nickel and adhesive~* Pregnant women, breastfeeding women~* Or any other criteria as appreciated by the study investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Group (Type: EXPERIMENTAL): Using the Medtrum Pump A7+ during 3 months
- Control Group (Type: ACTIVE_COMPARATOR): using the usual Insulet Patch pump

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Llama Antibody, Rotavirus Diarrhoea, Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sex: Male~* Age: 6-24 months~* History of watery diarrhoea of 48 hours or less~* At least 4 liquid stools during the previous 24 hours~* No V. cholerae in a dark-field test microscopy~* Presence of rotavirus in stool as determined by ELISA~* Written informed consent for participation by respective parents/guardians~Exclusion Criteria:~* Systemic infection(s) requiring antibiotic treatment~* Severe malnutrition (W/H \<-3SD)~* History of bloody diarrhoea~* Patient unwilling to comply with study protocol~* Currently participating or have participated in another clinical trial during the last 3 weeks prior to this study.

- Gender: MALE
- Minimum Age: 6 Months
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- VHH (Type: ACTIVE_COMPARATOR): The active substance is VHH batch 203027.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo product

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Has rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis and treatment with Simponi® by autoinjector device is to be initiated for the first time~Exclusion Criteria:~* No specific exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with Rheumatoid Arthritis (Type: None): Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.
- Participants with Psoriatic Arthritis (Type: None): Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.
- Participants with Ankylosing Spondylitis (Type: None): Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed written informed consent.~2. Age ≥ 18 years old (or minimum age based upon local regulations)~3. Unresectable locally advanced or metastatic histologically proven HER2+ gastroesophageal junction (GEJ) or gastric cancer. Gastric Cancer Expansion Phase will include only gastric cancer patients with 3+ HER2 positivity.~4. HER2+ as 3+ (as defined in AJCC staging manual 8th edition) by IHC or in-situ hybridation (ISH) amplified.~5. Have received prior treatment with trastuzumab.~6. Have received treatment with at least one or more lines of cytotoxic chemotherapy in the metastatic setting.~7. Resolution of chemotherapy, immunotherapy or radiation-related toxicities.~8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~9. Life expectancy ≥ 12 weeks.~10. Measurable disease as per RECIST 1.1 criteria.~Exclusion Criteria:~1. Patients with symptomatic central nervous system (CNS) metastases.~2. Patients with any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment.~3. History of prior allogeneic bone marrow, stem-cell or solid organ transplantation.~4. Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the 3 weeks prior to the initiation of study drug.~5. Treatment with radiation therapy within 3 weeks prior to the initiation of study drug administration.~6. Treatment with corticosteroids (≥10 mg per day prednisone or equivalent) or other immune suppressive drugs within the 14 days prior to the initiation of study drug administration.~7. History of clinically-significant cardiovascular disease.~8. Clinically-significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation.~9. History of (non-infectious) pneumonitis that required steroids or presence of active pneumonitis~10. Clinically-significant gastrointestinal disorders, such as perforation, gastrointestinal bleeding, or diverticulitis.~11. Evidence of active viral, bacterial, or systemic fungal infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Margetuximab 10 mg/kg plus pembrolizumab 200 mg (Type: EXPERIMENTAL): margetuximab administered in combination with pembrolizumab
- Cohort 2: Margetuximab 15 mg/kg plus pembrolizumab 200 mg (Type: EXPERIMENTAL): margetuximab administered in combination with pembrolizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Natural Killer (NK) Cell Transplantation for AML

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with AML that is in complete remission, is relapsed or refractory, or with increasing minimal residual disease.~* Participants in complete remission must have recovered from toxicity of previous therapy and have evidence of bone marrow recovery~* Participants who had prior stem cell transplant (SCT) must have no evidence of GVHD and 60 or more days have elapsed since the SCT.~Exclusion Criteria:~* Participants who are pregnant~* Participants with inadequate renal, liver, or pulmonary functions

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Stratum 1 (Type: EXPERIMENTAL): Stratum 1 (AML in complete remission)~Cyclophosphamide 60 mg/kg IV Day -7 Fludarabine 25 mg/m2/day IV Days -6 through -2 Donor pheresis Day -1 Start IL-2 on Day -1, then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0
- Stratum 2 (Type: EXPERIMENTAL): Stratum 2 (AML that is refractory or relapsed or AML with increasing minimal residual disease)~Clofarabine 40 mg/m2 IV, days -6 through -2 Etoposide 100 mg/m2 IV, days -6 through -2 Cyclophosphamide 400 mg/m2 IV, days -6 through 02 Donor pheresis Day -1 Start IL-2 Day -1, and then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1) age 18-80 years~* 2) American Society of Anesthesiologist (ASA) classification score I\~III~Exclusion Criteria:~* 1) allergic to tranexamic acid~* 2) preoperative seizures~* 3) history of thrombotic disease~* 4) chronic kidney disease~* 5) breastfeeding or pregnancy~* 6) refuse to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TXA group (Type: ACTIVE_COMPARATOR): The TXA group will receives Tranexamic acid intraoperative.
- Placebo group (Type: PLACEBO_COMPARATOR): The TXA group will receives 0.9% saline intraoperative.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Belimumab Administered Subcutaneously to Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Healthy subjects defined as no clinically relevant abnormalities identified by a detailed medical history, full physical exam, 12-lead electrocardiogram (ECG), and clinical laboratory tests.~* Body weight between 45 to 120 kg (99 to 264 lbs).~* Must agree to use effective contraception throughout the study and for 14 weeks after administration of belimumab.~* Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures.~Key Exclusion Criteria:~* Pregnant or nursing.~* Test positive for drugs or alcohol or have had a drug or alcohol dependence within the past year.~* Have used any prescription medicines within the past 30 days or herbal/botanical supplements within the past 7 days or anticipate use during the study. May use prescription contraceptives, hormone replacement therapy, and over-the-counter medicines such as antihistamines or nutritional support such as vitamins, minerals, or amino acids.~* Have received a live vaccine within the past 30 days or anticipate receipt of a live vaccine during the study and within 4 months after last injection of belimumab.~* Have a history of an allergic or anaphylactic reaction to drugs, food, or insect bite or sting requiring medical intervention.~* Have a history of allergic reaction to contrast agents or biological medicines.~* Have participated in a clinical trial and received an experimental medicine within the past 60 days.~* Have received treatment with a B cell targeted therapy at any time.~* Have required management of an infection within the past 14 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Belimumab IV 240 mg (Type: ACTIVE_COMPARATOR): None
- Belimumab SC 2 x 120 mg (Type: EXPERIMENTAL): None
- Belimumab SC 1 x 240 mg (Type: EXPERIMENTAL): None
- Belimumab SC 1 x 200 mg (Type: EXPERIMENTAL): None
- Belimumab SC 2 x 120 mg weekly (Type: EXPERIMENTAL): None
- Belimumab SC 1 x 200 mg weekly (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 18-65 years of age, diagnosed with asthma for at least 1 year;~2. Refractory asthma, defined as reporting that their asthma has not been completely controlled in the past 3 months despite continuous treatment with high-dose inhaled corticosteroids (ICS) and an additional controller medication, with or without continuous oral corticosteroids (OCS)~Exclusion Criteria:~1. Current smoking or smoking history of greater than 10 pack-years~2. Any other significant respiratory or cardiac disease, or the presence of clinically important comorbidities, including uncontrolled diabetes, uncontrolled coronary artery disease~3. If subject cannot undergo bronchoscopy procedure due to safety reasons~4. Previous treatment with Imatinib~5. A history of acute heart failure or chronic left sided heart failure~6. Uncontrolled systemic arterial hypertension~7. History of major bleeding or intracranial hemorrhage~8. History of immunodeficiency diseases, including HIV~9. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer~10. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~11. Diagnosis of Hepatitis B or C.~12. History of alcohol abuse within 6 months of screening.~13. History of illicit drug abuse within 6 months of screening.~14. Regular use of anticoagulants (eg: Warfarin Sodium, Coumadin), amiodarone, carbamazepine, Cyclosporine, Rifampicin, or reverse transcriptase inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib mesylate (Type: ACTIVE_COMPARATOR): Group on active imatinib treatment
- Placebo (Type: PLACEBO_COMPARATOR): Group on Placebo treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Sulfate Improves Postoperative Analgesia in Laparoscopic Gynecologic Surgeries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II female patients undergoing laparoscopic gynecologic oncology surgeries, for treatment of cancer~Exclusion Criteria:~* chronic pain, cardiovascular, hepatic or renal disease, neuromuscular disease, diabetes, drugs or alcohol abuse, obesity, patients treated with calcium channel blockers or magnesium, allergy or contraindication to any of the drugs studied.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ketorolac (Type: ACTIVE_COMPARATOR): intravenous ketorolac (30 mg) is injected in bolus, followed by continuous infusion of saline solution (Group K) during the surgical procedure
- magnesium (Type: EXPERIMENTAL): intravenous magnesium sulfate (20 mg/kg) is injected in bolus, followed by continuous infusion of magnesium sulfate (2 mg/kg/h) (Group M) during the surgical procedure
- saline (Type: PLACEBO_COMPARATOR): intravenous saline solution (20 ml) is injected in bolus, followed by continuous infusion of saline infusion during the entire procedure (Group S).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Must have signed consent for Amendment 5~* Must have completed visit 62 of the core IRIS trial or be in follow-up~* Must be on STI571 treatment~* If on IFN treatment, must be willing to cross over to STI571 treatment~Exclusion criteria:~* Patients who have discontinued from the study and are in follow-up~* Patients who are on IFN treatment and do not want to cross over to STI571 treatment~* Patients who have not consented to amendment 5~* Patients who did not complete the amendment 5 protocol~Additional protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- imatinib (STI571) (Type: EXPERIMENTAL): In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10\^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m\^2/day (max 40 mg) SC injection for 10 days every month. Maximum study duration was 11.5 years.
- IFN-a+Ara-C (Type: ACTIVE_COMPARATOR): In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m\^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10\^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete